NCT04741789 2026-03-16
Managed Access Programs for INC280, Capmatinib
Novartis
No longer available
Clinical Trials
8 trialsNCT04507503 2026-03-10
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Taiho Oncology, Inc.
Approved for marketing
NCT06915766 2026-03-09
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
Available
NCT06948955 2026-03-09
Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors
Cogent Biosciences, Inc.
Available
NCT06443944 2026-03-06
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
CG Oncology, Inc.
Available
NCT07215832 2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT06799221 2026-02-27
Expanded Access Program for OOS Obe-cel
Autolus Limited
Available
NCT07399015 2026-02-18
Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC
Endevica Bio
No longer available